Lorenzo Tallarigo Buys 29,685 Shares of Oxford BioMedica plc (OXB) Stock
Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo bought 29,685 shares of Oxford BioMedica plc stock in a transaction dated Friday, September 22nd. The shares were bought at an average cost of GBX 9 ($0.12) per share, with a total value of £2,671.65 ($3,602.06).
Shares of Oxford BioMedica plc (LON:OXB) traded up 2.24% on Friday, reaching GBX 9.11. 886,161 shares of the company’s stock traded hands. The stock’s market cap is GBX 281.34 million. Oxford BioMedica plc has a 52-week low of GBX 2.98 and a 52-week high of GBX 11.25. The firm’s 50-day moving average is GBX 8.85 and its 200-day moving average is GBX 6.66.
Several research firms recently commented on OXB. N+1 Singer raised their price objective on shares of Oxford BioMedica plc from GBX 8.70 ($0.12) to GBX 10.20 ($0.14) and gave the stock a “hold” rating in a report on Thursday, August 31st. Jefferies Group LLC reaffirmed a “buy” rating and issued a GBX 13 ($0.18) price objective on shares of Oxford BioMedica plc in a report on Thursday, August 31st. Shore Capital reaffirmed a “not rated” rating on shares of Oxford BioMedica plc in a report on Thursday, July 13th. Finally, Peel Hunt began coverage on shares of Oxford BioMedica plc in a report on Tuesday. They issued a “buy” rating and a GBX 13 ($0.18) price objective for the company.
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.